Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination

被引:244
|
作者
Schultz, N
Lopez, E
Saleh-Gohari, N
Helleday, T
机构
[1] Univ Sheffield, Sch Med, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England
[2] Stockholm Univ, Arrhenius Lab, Dept Genet & Cellular Toxicol, S-10691 Stockholm, Sweden
关键词
D O I
10.1093/nar/gkg703
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cells with non-functional poly(ADP-ribose) polymerase (PARP-1) show increased levels of sister chromatid exchange, suggesting a hyper recombination phenotype in these cells. To further investigate the involvement of PARP-1 in homologous recombination (HR) we investigated how PARP-1 affects nuclear HR sites (Rad51 foci) and HR repair of an endonuclease-induced DNA double-strand break (DSB). Several proteins involved in HR localise to Rad51 foci and HR-deficient cells fail to form Rad51 foci in response to DNA damage. Here, we show that PARP-1 mainly does not localise to Rad51 foci and that Rad51 foci form in PARP-1(-/-) cells, also in response to hydroxyurea. Furthermore, we show that homology directed repair following induction of a site-specific DSB is normal in PARP-1-inhibited cells. In contrast, inhibition or loss of PARP-1 increases spontaneous Rad51 foci formation, confirming a hyper recombination phenotype in these cells. Our data suggest that PARP-1 controls DNA damage recognised by HR and that it is not involved in executing HR as such.
引用
收藏
页码:4959 / 4964
页数:6
相关论文
共 50 条
  • [31] Involvement of poly(ADP-ribose) polymerase-1 (PARP-1) in the developement and treatment of hepatocellular carcinoma
    Quiles, R.
    Extremera, A. Ruiz
    Salmeron, J.
    Caballero, T.
    Munoz-Rueda, P.
    Casado, J.
    Oliver, F. J.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S139 - S139
  • [32] Poly (ADP-ribose) polymerase-1 (PARP-1) activity in normal and cancerous human endometrium
    Monist, M.
    Postawski, K.
    Romanek, K.
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2009, 24 : S69 - S69
  • [33] Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
    Zhang, Zhimin
    Chang, Xinyue
    Zhang, Chixiao
    Zeng, Shenxin
    Liang, Meihao
    Ma, Zhen
    Wang, Zunyuan
    Huang, Wenhai
    Shen, Zhengrong
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 1606 - 1615
  • [34] Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1)
    Steinhagen, H
    Gerisch, M
    Mittendorf, J
    Schlemmer, KH
    Albrecht, B
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (21) : 3187 - 3190
  • [35] Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis
    Nosho, Katsuhiko
    Yamamoto, Hiroyuki
    Mikami, Masashi
    Taniguchi, Hiroaki
    Takahashi, Taiga
    Adachi, Yasushi
    Imamura, Akimichi
    Imai, Kohzoh
    Shinomura, Yasuhisa
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (14) : 2374 - 2381
  • [36] Functional regulation of the Werner protein by poly(ADP-ribose) and PARP-1
    Veith, Sebastian
    Popp, Oliver
    Fahrer, Jorg
    Burkle, Alexander
    Mangerich, Aswin
    EXPERIMENTAL GERONTOLOGY, 2013, 48 (07) : 691 - 691
  • [37] Role of poly(ADP-ribose) Polymerase (PARP) activation in the pathogenesis of periodontitis
    Lohinai, Z
    Komjati, K
    Mabley, JG
    Feher, E
    Marton, A
    Szabo, C
    FASEB JOURNAL, 2003, 17 (05): : A1364 - A1364
  • [38] Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
    Gottipati, Ponnari
    Vischioni, Barbara
    Schultz, Niklas
    Solomons, Joyce
    Bryant, Helen E.
    Djureinovic, Tatjana
    Issaeva, Natalia
    Sleeth, Kate
    Sharma, Ricky A.
    Helleday, Thomas
    CANCER RESEARCH, 2010, 70 (13) : 5389 - 5398
  • [39] On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
    Luo, Xin
    Kraus, W. Lee
    GENES & DEVELOPMENT, 2012, 26 (05) : 417 - 432
  • [40] New inhibitors of poly(ADP-ribose) polymerase (PARP)
    Peukert, S
    Schwahn, U
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (11) : 1531 - 1551